Quadriga BioSciences, Inc.
1111 West El Camino Real Suite 109-234
Sunnyvale, CA 94087
Quadriga Biosciences, Inc. is an emerging privately-held discovery-stage life sciences company developing novel, targeted cytotoxic small molecules for the treatment of cancer as a personalized medicine. The company’s objective is to develop a pipeline of novel targeted therapeutics built on its transporter platform technology. This platform may also be used to develop diagnostics, imaging and radiopotentiation agents. Our lead therapeutic program is currently in preclinical development and is targeting a transporter that is frequently upregulated in solid and hematologic cancers and associated with poor prognosis. Quadriga expects to file an IND for Phase 1 clinical trial in 2016. This trial will be designed to yield early clinical proof-of-concept in the target patient population with the objective that such achievement would immediately lead to well-defined registrational studies to support market approval.
Blood & Lymphatic Diseases; Cancer; Metabolic/Endocrinology Disorders
Drug Delivery Technologies
Drug Delivery; Imaging
Clinical Development Stage